To evaluate the impact of surgical care on bioprosthetic valve durability and patient quality of life in carcinoid heart disease.
Assessment of bioprosthetic valve performance in CHD patients
Evaluation of quality of life metrics
Longitudinal follow-up of patient outcomes
Bioprosthetic valves showed exceptional durability lasting 17 years
Improved quality of life reported by patients post-surgery
Abstract
With multidisciplinary oncologic and surgical care, bioprosthetic valves in CHD patients can demonstrate exceptional durability (17 years), offering prolonged survival and quality of life.